Alpha Tau Medical stock completes 48 patient trial enrollment
Published on 09/30/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Alpha Tau Medical stock is anchored by a 48 patient pancreatic cancer study completed on August 31, 2026, giving the clinical-stage biotechnology company a concrete next milestone. The IMPACT trial expanded from 12 patients to 48 across 10 centers, with initial data targeted for early 2027, according to Alpha Tau.
Pancreatic study reaches 48 patients
The IMPACT program evaluates Alpha DaRT delivered with first-line chemotherapy for newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. Enrollment increased fourfold from the original 12 patient design, and the completed study now moves into follow-up and data maturation across the 48 participants.
The operational signal is important because the company said the study was expanded three times after demand from participating clinicians and patients. Investing.com reported on September 16, 2026 that the pancreatic data from all 48 patients are expected in early 2027.
Cash supports the clinical program
Alpha Tau's financial position remains central to the timeline. In the six months ended June 30, 2026, the company reported a net loss of USD 68.8 million, compared with USD 18.8 million in the prior-year period, while cash, cash equivalents and related deposits totaled USD 104.8 million.
Research and development expense reached USD 20.9 million for the same six-month period, up from USD 14.2 million a year earlier. Quartr said management projects a cash runway of at least two years as clinical trials expand and manufacturing scales.
Nasdaq quote stays near yearly high
Alpha Tau Medical was last quoted at USD 15.19 on Nasdaq on September 29, 2026 at 4:00 p.m. ET. That level was USD 0.60, or 3.80 percent, below the 52-week high of USD 15.79 and well above the 52-week low of USD 3.43.
The market capitalization stood at USD 1.4 billion as of September 30, 2026. The valuation leaves the pancreatic readout and the broader Alpha DaRT trial pipeline as the company specific checkpoints most likely to shape the next phase of the stock story.
Alpha Tau Medical stock facts
- Company: Alpha Tau Medical Ltd
- Ticker: DRTS
- Primary exchange: Nasdaq
- Market capitalization: USD 1.4 billion (as of September 30, 2026)
- 52-week range: USD 3.43-15.79 (as of September 29, 2026)
- Sector / Industry: Healthcare / Biotechnology
